
BiBBInstruments announces date for conversion of exercised warrants of series TO 1 into shares

BiBBInstruments AB (“BiBB” or the “Company”) announces that the Swedish Companies Registration Office has registered the shares subscribed for through the exercise of warrants of series TO 1 (“TO 1”). A total of 514,916 TO 1 were exercised for the subscription of 514,916 shares in the Company. This increases the number of shares in the Company to 40,739,302 and the share capital in the Company increases by SEK 43,767.86 to SEK 3,462,840.67. The record date is June 26, 2025, after which it is expected that the shares will be admitted to trading on Spotlight Stock Market and distributed to subscribers’ VP accounts/custody accounts as of June 30, 2025.

Advisors

DNB Carnegie SME and Setterwalls Advokatbyrå AB acted as financial and legal advisors to BiBB in connection with the rights issue through which TO 1 were issued.

This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.

For more information about BiBB, please contact:

Fredrik Lindblad, CEO

E-mail: fredrik.lindblad@bibbinstruments.com

Phone: +46 70 899 94 86

www.bibbinstruments.com

About BiBB

BiBBInstruments AB (“BiBB”) develops and manufactures EndoDrill® – the world’s first market-cleared, powered biopsy instrument for endoscopy. EndoDrill® enables rapid and high-quality core needle biopsies (CNB) for the diagnosis of serious cancers, including gastric, pancreatic, liver, lung, and bladder cancer. The product portfolio targets the fast-growing global market for endoscopic ultrasound-guided biopsy instruments (EUS/EBUS). EndoDrill® GI is FDA-cleared and CE-marked, with U.S. launch starting in 2025 in collaboration with TaeWoong Medical USA. EndoDrill® EBUS and EndoDrill® URO were CE-marked in 2024 and are planned for gradual launch. BiBB was founded by Dr Charles Walther and is headquartered at Medicon Village in Lund, Sweden. The share (BiBB) is listed on Spotlight Stock Market.

IMPORTANT INFORMATION

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in BiBB. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in BiBB has only been made through the prospectus published by BiBB on December 19, 2024.